Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Time in blood glucose range 70 to 180 mg/dL and survival rate in critically ill patients: A retrospective observational study

View ORCID ProfileHiromu Naraba, View ORCID ProfileTadahiro Goto, View ORCID ProfileToru Shirakawa, View ORCID ProfileTomohiro Sonoo, View ORCID ProfileNaoki Kanda, View ORCID ProfileHidehiko Nakano, View ORCID ProfileYuji Takahashi, Hideki Hashimoto, View ORCID ProfileKensuke Nakamura
doi: https://doi.org/10.1101/2020.08.31.20184994
Hiromu Naraba
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
4TXP Medical Co., Ltd., 3-13-508 Nihonbashiyokoyama-cho, Chuo-ku, Tokyo, 103-0003, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hiromu Naraba
  • For correspondence: naraba-hok@umin.ac.jp
Tadahiro Goto
2Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan
4TXP Medical Co., Ltd., 3-13-508 Nihonbashiyokoyama-cho, Chuo-ku, Tokyo, 103-0003, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tadahiro Goto
Toru Shirakawa
3Public Health, Osaka University Graduate School Medicine, 2-2 Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
4TXP Medical Co., Ltd., 3-13-508 Nihonbashiyokoyama-cho, Chuo-ku, Tokyo, 103-0003, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Toru Shirakawa
Tomohiro Sonoo
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
4TXP Medical Co., Ltd., 3-13-508 Nihonbashiyokoyama-cho, Chuo-ku, Tokyo, 103-0003, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomohiro Sonoo
Naoki Kanda
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Naoki Kanda
Hidehiko Nakano
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hidehiko Nakano
Yuji Takahashi
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuji Takahashi
Hideki Hashimoto
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kensuke Nakamura
1Department of Emergency and Critical Care Medicine, Hitachi General Hospital, 2-1-1 Jonan-cho, Hitachi-shi, Ibaraki, 317-0077, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kensuke Nakamura
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective Time in targeted blood glucose range (TIR) 70-140 mg/dL has been associated with an increased risk of mortality in critically ill patients. Nevertheless, it remains unclear whether TIR is associated with 28-day mortality in critically ill patients under glycemic control with a less tight target glucose range of 70-180 mg/dL. We aimed to assess whether TIR 70-180 mg/dL was associated with 28-day mortality and to identify the optimal TIR.

Design A retrospective observational study.

Setting Data from a tertiary care centre in Japan, from 1 January 2016 through 31 October 2019.

Participants 1,230 adult patients admitted to the intensive care unit for more than three days.

Outcome measure The primary outcome was 28-day mortality.

Results Of 1,230 patients, patients with HbA1c ≥6.5% had a higher 28-day mortality than those with <6.5% (32.0% vs. 22.7%; p=0.003). In the multivariate logistic regression, TIR <80% was associated with an increased risk of 28-day mortality in patients with HbA1c <6.5% with an adjusted odds ratio (OR) of 1.88 (95% confidence interval [CI]: 1.36-2.61). When using 10% incremental TIR as a categorical variable, lower TIR was associated with worse 28-day mortality compared to TIR ≥90% in patients with HbA1c <6.5% (e.g., adjusted OR of TIR <60%, 3.62 [95%CI 2.36-5.53]). Similar associations were found in the analyses using the COX proportional hazards model. In addition, sensitivity analyses using TIR of the first three days showed that the overall associations were consistent with primary analyses.

Conclusions Our study demonstrated that lower TIR 70-180 mg/dL was associated with higher 28-day mortality in nondiabetic critically ill patients.

Article Summary

Strengths and limitations of this study
  • This is the first study to evaluate the association between less tight TIR (70-180 mg/dl) and mortality in critically ill patients.

  • We found consistent results in the analyses using logistic regression model and Cox proportional hazard model.

  • The primary findings were also observed in the analysis using TIR in the first three days.

  • We did not use a continuous glucose monitoring device to calculate TIR.

  • Due to the nature of the single-centre study design, the generalizability of the findings might be limited.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

There is no funder/sponsor support for design and conduct of the study, for collection, management, analysis, and interpretation of the data, for preparation, review, or approval of the manuscript, or for decisions to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics Committee of Hitachi General Hospital

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The email address of each author: Tadahiro Goto: tag695{at}mail.harvard.edu

  • Toru Shirakawa: shirakawa{at}pbhel.med.osaka-u.ac.jp

  • Tomohiro Sonoo: tomohiro.sonoo{at}txpmedical.com

  • Naoki Kanda: nakanda-tky{at}umin.ac.jp

  • Hidehiko Nakano: hinakano-tky{at}umin.ac.jp

  • Yuji Takahashi: yuji.mail{at}icloud.com

  • Hideki Hashimoto: hideg1018{at}gmail.com

  • Kensuke Nakamura: knakamura-tky{at}umin.ac.jp

Data Availability

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Time in blood glucose range 70 to 180 mg/dL and survival rate in critically ill patients: A retrospective observational study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Time in blood glucose range 70 to 180 mg/dL and survival rate in critically ill patients: A retrospective observational study
Hiromu Naraba, Tadahiro Goto, Toru Shirakawa, Tomohiro Sonoo, Naoki Kanda, Hidehiko Nakano, Yuji Takahashi, Hideki Hashimoto, Kensuke Nakamura
medRxiv 2020.08.31.20184994; doi: https://doi.org/10.1101/2020.08.31.20184994
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Time in blood glucose range 70 to 180 mg/dL and survival rate in critically ill patients: A retrospective observational study
Hiromu Naraba, Tadahiro Goto, Toru Shirakawa, Tomohiro Sonoo, Naoki Kanda, Hidehiko Nakano, Yuji Takahashi, Hideki Hashimoto, Kensuke Nakamura
medRxiv 2020.08.31.20184994; doi: https://doi.org/10.1101/2020.08.31.20184994

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3826)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)